Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal

Minoryx’s preclinical data for leriglitazone…

ExeVir Bio Appoints Michel Kazatchkine and Stef Heylen to the Board of Directors

ExeVir Bio Appoints Michel Kazatchkine…

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

Immunic, Inc. Announces 200 Patients…

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

European Investment Bank provides Minoryx…

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

EIB Provides Immunic With up…

Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development

Confo Therapeutics Announces Selection of…

eTheRNA extends senior management team with appointment of Michael Mulqueen as VP Business Development

eTheRNA extends senior management team…

Ona Therapeutics is named as one of Fierce Biotech’s “Fierce 15” Biotech Companies of 2020

Ona Therapeutics is named as…

Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

Minoryx Therapeutics and Sperogenix Therapeutics…

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

Immunic, Inc. Announces Dosing of…